Meta-Analysis: Cardiovascular Events Associated with Nonsteroidal Anti-inflammatory Drugs

American Journal of Medicine

Volumn 119, Issue 7, 2006, Pages 552-559

  Salpeter, Shelley R ^a,b   Gregor, Peter ^b   Ormiston, Thomas M ^b   Whitlock, Richard ^c   Raina, Parminder ^c   Thabane, Lehana ^c,d   Topol, Eric J ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Cyclooxygenase 2 inhibitors; Meta analysis; Non steroidal anti inflammatory agents

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; ARTHROPATHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA BASE; DEATH; DRUG INDICATION; DRUG SAFETY; HEART INFARCTION; HEART PROTECTION; HUMAN; META ANALYSIS; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; HUMANS; JOINT DISEASES; NAPROXEN; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 33745921486     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.10.056     Document Type: Article

References (60)

1. U.S. Food and Drug Administration. Internal analgesic, antipyretic and antirheumatic drug products for over-the-counter human use. Available at: http://www.fda.gov/ohrms/dockets/98fr/082102b.pdf. Accessed January 29, 2005.
2. U.S. Food and Drug Administration. Approval of naproxen sodium. Available at: http://www.fda.gov/bbs/topics/NEWS/NEW00456.html. Accessed January 29, 2005.
3. U.S. Food and Drug Administration. FDA approves celebrex for arthritis. FDA Talk Paper. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS00932.html. Accessed January 29, 2005.
4. U.S. Food and Drug Administration. FDA approves vioxx for osteoarthritis, pain and menstrual pain. FDA Talk Paper. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS00956.html. Accessed January 29, 2005.
5. Vane J. The evolution of non-steroidal anti-inflammatory drugs and their mechanisms of action. Drugs 33 Suppl 1 (1987) 18-27
6. Schafer A.I. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 35 (1995) 209-219
7. Sanmuganathan P.S., Ghahramani P., Jackson P.R., Wallis E.J., and Ramsay L.E. Aspirin for primary prevention of coronary heart disease. safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85 (2001) 265-271
8. Bombardier C., Laine L., Reicin A., et al., VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
9. Finckh A., and Aronson M.D. Cardiovascular risks of cyclooxygenase-2 inhibitors. where we stand now. Ann Intern Med 142 (2005) 212-214
10. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., and Egger M. Risk of cardiovascular events and rofecoxib. cumulative meta-analysis. Lancet 364 (2004) 2021-2029
11. Topol E.J. Arthritis medicines and cardiovascular events-"house of coxibs.". JAMA 293 (2005) 366-368
12. Valdecoxib meta-analysis find increased cardiovascular risk. Available at: http://www.formularyjournal.com/formulary/article/articleDetail.jsp?id=1 41435. Accessed January 29, 2005.
13. Furberg C.D., Psaty B.M., and FitzGerald G.A. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 111 (2005) 249
14. Garcia Rodriguez L.A., Varas C., and Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 11 (2000) 382-387
15. Rahme E., Pilote L., and LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 162 (2002) 1111-1115
16. Watson D.J., Rhodes T., Cai B., and Guess H.A. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 162 (2002) 1105-1110
17. Solomon D.H., Glynn R.J., Levin R., and Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 162 (2002) 1099-1104
18. Ray W.A., Stein C.M., Hall K., Daugherty J.R., and Griffin M.R. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. an observational cohort study. Lancet 359 (2002) 118-123
19. Ray W.A., Stein C.M., Daugherty J.R., Hall K., Arbogast P.G., and Griffin M.R. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360 (2002) 1071-1073
20. MacDonald T.M., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
21. Solomon D.H., Schneeweiss S., Levin R., and Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 44 (2004) 140-145
22. Mamdani M., Juurlink D.N., Lee D.S., et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients. a population-based cohort study. Lancet 363 (2004) 1751-1756
23. Shaya F.T., Blume S.W., Blanchette C.M., Weir M.R., and Mullins C.D. Selective cyclooxygenase-2 inhibition and cardiovascular effects. an observational study of a medicaid population. Arch Intern Med 165 (2005) 181-186
24. Kimmel S.E., Berlin J.A., Reilly M., et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142 (2005) 157-164
25. National Institutes of Health. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. US Department of Health and Human Services. Available at: http://www.nih.gov/news/pr/dec2004/od-20.htm. Accessed January 29, 2005.
26. Fleiss J.L. Statistical Methods for Rates and Proportions (1981), Wiley, New York, NY 217-234
27. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials. is blinding necessary?. Control Clin Trials 17 (1996) 1-12
28. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
29. Bekelman J.E., Li Y., and Gross C.P. Scope and impact of financial conflicts of interest in biomedical research. a systematic review. JAMA 289 (2003) 454-465
30. Altman D.G., and Bland J.M. Interaction revisited. the difference between two estimates. BMJ 326 (2003) 219
31. Aisen P.S., Schafer K.A., Grundman M., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. a randomized controlled trial. JAMA 289 (2003) 2819-2826
32. Edwards J.E., McQuay H.J., and Moore R.A. Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis. systematic review of randomised controlled trials. Pain 111 (2004) 286-296
33. Food and Drug Administration. Cardiovascular Safety Review: Rofecoxib Study 085. Food and Drug Administration. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf. Accessed January 19, 2005.
34. Food and Drug Administration. Cardiovascular Safety Review: Rofecoxib Study 090. Food and Drug Administration. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf. Accessed January 19, 2005.
35. Geusens P.P., Truitt K., Sfikakis P., et al. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. Scand J Rheumatol 31 (2002) 230-238
36. Geusens P., Alten R., Rovensky J., et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract 58 (2004) 1033-1041
37. Hawkey C.J., Laine L., Simon T., Quan H., Shingo S., and Evans J. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo. a multicentre, randomised, double blind study. Gut 52 (2003) 820-826
38. Konstam M.A., Weir M.R., Reicin A., et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104 19 (2001) 2280-2288
39. Moore R.A., Derry S., Makinson G.T., and McQuay H.J. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis. systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 7 (2005) R644-R665
40. Rogers J., Kirby L.C., Hempelman S.R., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43 (1993) 1609-1611
41. Saag K., van der Heijde D., Fisher C., et al., Osteoarthritis Studies Group. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs. a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 9 (2000) 1124-1134
42. Scharf S., Mander A., Ugoni A., Vajda F., and Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53 (1999) 197-201
43. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
44. Jones S.C. Relative thromboembolic risks associated with COX-2 inhibitors. Ann Pharmacother 39 (2005) 1249-1259
45. Reilly I.A., and FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo. implications for therapy with platelet inhibitory drugs. Blood 69 (1987) 180-186
46. Patrono C., Ciabattoni G., Patrignani P., et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72 (1985) 1177-1184
47. Favre L., Glasson P., Riondel A., and Vallotton M.B. Interaction of diuretics and non-steroidal anti-inflammatory drugs in man. Clin Sci (Lond) 64 (1983) 407-415
48. Favre L., Glasson P., and Vallotton M.B. Reversible acute renal failure from combined triamterene and indomethacin. a study in healthy subjects. Ann Intern Med 96 (1982) 317-320
49. Patak R.V., Mookerjee B.K., Bentzel C.J., Hysert P.E., Babej M., and Lee J.B. Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. Prostaglandins 10 (1975) 649-659
50. Salvetti A., Arzilli F., Pedrinelli R., Beggi P., and Motolese M. Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients. Eur J Clin Pharmacol 22 (1982) 197-201
51. Durao V., Prata M.M., and Goncalves L.M. Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet 2 (1977) 1005-1007
52. Abate M.A., Neely J.L., Layne R.D., and D'Alessandri R. Interaction of indomethacin and sulindac with labetalol. Br J Clin Pharmacol 31 (1991) 363-366
53. Oparil S., Horton R., Wilkins L.H., Irvin J., and Hammett D.K. Antihypertensive effect of enalapril in essential hypertension. role of prostacyclin. Am J Med Sci 294 (1987) 395-402
54. Koopmans P.P., van Megen T., Thien T., and Gribnau F.W. The interaction between indomethacin and captopril or enalapril in healthy volunteers. J Intern Med 226 (1989) 139-142
55. Kirch W., Stroemer K., Hoogkamer J.F., and Kleinbloesem C.H. The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril. Br J Clin Pharmacol 27 Suppl 2 (1989) 297S-301S
56. Conlin P.R., Moore T.J., Swartz S.L., et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 36 (2000) 461-465
57. Pope J.E., Anderson J.J., and Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153 (1993) 477-484
58. Johnson A.G., Nguyen T.V., and Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121 (1994) 289-300
59. Casserly I., and Topol E. Convergence of atherosclerosis and Alzheimer's disease. inflammation, cholesterol, and misfolded proteins. Lancet 363 (2004) 1139-1146
60. Ionnidis J.P., and Lau J. Pooling research results. benefits and limitations of meta-analysis. Jt Comm J Qual Improv 25 (1999) 462-469